Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success

Area of Science:

• Infectious Diseases
• Pharmacology
• Microbiology

Background:

• Tedizolid exhibits activity against Gram-positive pathogens, Mycobacterium, and Nocardia species.
• Limited real-world data exists on the long-term tolerability and clinical outcomes of tedizolid therapy.

Purpose of the Study:

• To evaluate the long-term tolerability and clinical success of tedizolid in a real-world setting.

Main Methods:

• Retrospective analysis of 37 patients receiving prolonged tedizolid therapy.
• Data collection on treatment duration, adverse effects, and clinical outcomes.

Main Results:

• The median duration of tedizolid therapy was 188 days (IQR, 62-493 days).
• Only 8.1% of patients experienced adverse effects leading to treatment discontinuation.
• Clinical success was achieved in 81.3% of evaluated patients.

Conclusions:

• Prolonged tedizolid therapy is generally well-tolerated.
• Tedizolid demonstrates high clinical success rates in real-world patient populations.